Bio-Techne approves Merck deal: what it means for Bio-Techne stock

Published on 10/07/2026 at 07:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck sets USD 73.00 cash value for Bio-Techne stock. Fiscal 2026 adjusted earnings per share was USD 0.52 and operating margin was 32.20 percent.

Bio-Techne, US09073M1045, Illustration mit AI erstellt.

Bio-Techne Corporation (ISIN US09073M1045) had a prior close of EUR 64.35 at Lang & Schwarz on October 5, 2026. On September 23, 2026, shareholders approved the proposed acquisition by Merck KGaA, a transaction that assigns a USD 73.00 cash value to each share, according to MarketScreener.

Cash value anchors the deal

The approval removes one shareholder hurdle, but the transaction still depends on customary closing conditions and remaining regulatory approvals. Bio-Techne expects the deal to close in late 2026 or early 2027, a timeline that keeps execution risk relevant for the stock.

The proposed consideration is a cash payment rather than a share exchange. That structure gives investors a clearly stated USD 73.00 transaction value, while the final outcome still depends on the deal closing on the expected schedule.

Fiscal figures show the operating base

Bio-Techne's latest fiscal 2026 quarterly release listed revenue of USD 321.20 million, adjusted gross margin of 69.20 percent, adjusted operating margin of 32.20 percent and adjusted earnings per share of USD 0.52, as shown on the company's investor-relations page. The figures give the takeover proposal an operating reference beyond the deal premium itself.

Bio-Techne develops reagents, analytical instruments and precision diagnostics for research and clinical markets. Its fiscal 2026 annual revenue was USD 1.22 billion and net income was USD 181.86 million, while operating cash flow reached USD 292.07 million.

Next report sets the next checkpoint

Investing.com lists November 3, 2026, as Bio-Techne's next earnings date. The same Nasdaq context shows a market capitalization of USD 11.3 billion and a 52-week range of USD 43.20 to USD 72.69 as of October 6, 2026.

The offer sets the market reference

The prior close at Lang & Schwarz was EUR 64.35 on October 5, 2026. The transaction value, fiscal 2026 operating figures and November 3 reporting date define the next factual checkpoints for the company.

The further course of trading is shown by the continuously updated real-time quote of Bio-Techne stock.